Name	Pamela S. Becker, MD, PhD
Current Position & Affiliation	Professor, Division of Leukemia, Department of Hematology and Hematopoietic Cell Transplantation and Department of Hematologic Malignancies Translational Research, Beckman Research Institute, City of Hope
Country	USA
Major Field	Acute Myeloid Leukemia, Hematopoietic Stem Cell Gene Therapy, Allogeneic Stem Cell Transplantation

Educational Background

Bachelor of Arts, Biochemical Sciences, Harvard University, Cambridge, MA, USA
Doctor of Medicine, Harvard Medical School-Massachusetts Institute of Technology Health Sciences and Technology Program, Boston, MA, USA
Doctor of Philosophy, Program on Cell and Developmental Biology, Division of Medical Sciences, Harvard Graduate School of Arts and Sciences, Cambridge, MA, USA
Internal Medicine Residency, Beth Israel Hospital and Harvard Medical School, Boston, MA
Postdoctoral Fellowship, Hematology Section, Yale University School of Medicine, New Haven, CT, USA

Professional Experience

2025 - Director, Adult Commercial Gene Therapy, Dept. of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA
2022 - Professor, Dept of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA
2020 - Affiliate Professor, Department of Medicine, Division of Hematology, University of Washington, Seattle, WA
2020 - 2022 Professor of Clinical Medicine and Co-Leader, Systems, Pathways & Targets Program, Chao Family Comprehensive Cancer Center, University of California, Irvine, CA
2017 - 2020 Professor, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
2014 - 2020 Professor of Medicine, Division of Hematology, University of Washington, Seattle, WA
2013 - 2017 Associate Member, Clin Res Div, Fred Hutchinson Cancer Research Center, Seattle, WA
2003 - 2014 Associate Professor of Medicine, Div of Hematology, University of Washington, Seattle, WA
2000 - 2003 Division Chief, Gene Therapy, University of Massachusetts Medical School, Worcester, MA
1999 - 2003 Associate Professor, Dept of Medicine and Cell Biology, University of Massachusetts Medical School, Worcester, MA
1993 - 1999 Assistant Professor, Dept of Medicine and Cell Biology, University of Massachusetts Medical School, Worcester, MA
1992 - 1993 Instructor, Hematology Section, Yale University School of Medicine, New Haven, CT

1991 - 1992 Associate Research Scientist, Hematology Section, Yale University School of Medicine, New Haven, CT

Other Experience and Professional Memberships

Member, American Society of Hematology
Member, American Society of Clinical Oncology
Member, American Association for Cancer Research
Member, Society for Functional Precision Medicine
Member, American Society for Gene and Cell Therapy
Member, American Society for Transplantation and Cellular Therapy
2024-28 Standing Member, Clinical Oncology Study Section (CONC), NIH
2023-present Member, Subcommittee on Precision Medicine, American Society of Hematology
2018-2020 Chair, Hematopoietic Growth Factors Panel, National Comprehensive Cancer Network
2013-2018 Vice Chair, Myeloid Growth Factors Committee, National Comprehensive Cancer Network
2012-2016 Standing Member, Training Mechanism Review Committee (T32 Grant Reviews), NHLBI, NIH

Main Scientific Publications

1. Qin G, Dai J, Chien S, Martins TJ, Loera B, Nguyen QH, Oakes ML, Tercan B, Aguilar B, Hagen L, McCune J, Gelinas R, Monnat RJ Jr, Shmulevich I, Becker PS. Mutation Patterns Predict Drug Sensitivity in Acute Myeloid Leukemia. Clin Cancer Res. 2024 Jun 14;30(12):2659-2671. PubMed Central PMCID: PMC11176916.
2. Kamath-Loeb AS, Shen JC, Schmitt MW, Kohrn BF, Loeb KR, Estey EH, Dai J, Chien S, Loeb LA, Becker PS. Accurate detection of subclonal variants in paired diagnosis-relapse acute myeloid leukemia samples by next generation Duplex Sequencing. Leuk Res. 2022 Apr;115:106822. PubMed Central PMCID: PMC9014797.
3. DeAngelo DJ, Jonas BA, Liesveld JL, Bixby DL, Advani AS, Marlton P, Magnani JL, Thackray HM, Feldman EJ, O'Dwyer ME, Becker PS. Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia. Blood. 2022 Feb 24;139(8):1135-1146. PubMed Central PMCID: PMC11017789.
4. Lee SI, Celik S, Logsdon BA, Lundberg SM, Martins TJ, Oehler VG, Estey EH, Miller CP, Chien S, Dai J, Saxena A, Blau CA, Becker PS. A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia. Nat Commun. 2018 Jan 3;9(1):42. PubMed Central PMCID: PMC5752671.
5. Becker PS, Tse WT, Lux SE, Forget BG. Beta spectrin Kissimmee: a spectrin variant associated with autosomal dominant hereditary spherocytosis and defective binding to protein 4.1. J Clin Invest. 1993 Aug;92(2):612-6. PubMed Central PMCID: PMC294892.
6. Becker PS, Taylor JA, Trobridge GD, Zhao X, Beard BC, Chien S, Adair J, Kohn DB, Wagner JE, Shimamura A, Kiem HP. Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector. Gene Ther. 2010 Oct;17(10):1244-52. PubMed Central PMCID: PMC2927804.

7. Coffey DG, Cowan AJ, DeGraaff B, Martins TJ, Curley N, Green DJ, Libby EN, Silbermann R, Chien S, Dai J, Morales A, Gooley TA, Warren EH, Becker PS. High-Throughput Drug Screening and Multi-Omic Analysis to Guide Individualized Treatment for Multiple Myeloma. JCO Precis Oncol. 2021;5 PubMed Central PMCID: PMC8232547.
8. Halpern AB, Martins TJ, Jonlin EC, Dai J, Chien S, Becker PS. Case of Chemotherapy-Refractory, RAS-Mutated Chronic Myelomonocytic Leukemia Responsive to Single-Agent Trametinib Based on Results From a High-Throughput Drug Screen. JCO Precis Oncol. 2020 Nov;4:1367-1373. PubMed PMID: 35050791.
9. Ghobrial IM, Liu CJ, Redd RA, Perez RP, Baz R, Zavidij O, Sklavenitis-Pistofidis R, Richardson PG, Anderson KC, Laubach J, Henrick P, Savell A, Reyes K, Hornburg K, Chuma S, Sabbatini P, Robbins MD, Becker PS. A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. Clin Cancer Res. 2020 Jan 15;26(2):344-353. PubMed Central PMCID: PMC11753616.
10. Huang JC, Basu SK, Zhao X, Chien S, Fang M, Oehler VG, Appelbaum FR, Becker PS. Mesenchymal stromal cells derived from acute myeloid leukemia bone marrow exhibit aberrant cytogenetics and cytokine elaboration. Blood Cancer J. 2015 Apr 10;5(4):e302. PubMed Central PMCID: PMC4450324.